Navidea Biopharmaceuticals Completes License for Parkinson's Disease Imaging Agent

Navidea Biopharmaceuticals, Inc.

today announced that it has entered into an agreement with Alseres Pharmaceuticals, Inc. (Alseres) to license [123I]-E-IACFT Injection (CFT), an Iodine-123 radiolabeled imaging agent being developed as an aid in the diagnosis of Parkinson's disease and other movement disorders, with a potential use as a diagnostic aid in dementia. “The diagnostic dilemma in movement disorders remains a pressing medical need that will continue to escalate as our world's population ages,” said Dr. Mark Pykett, President and CEO of Navidea. “The addition of the CFT program is consistent with our growth strategy to build our precision radiopharmaceutical pipeline with later-stage, high-value diagnostics aimed at important medical needs.”